Evaluation of the efficacy of Afentanil in painless gastroscopy in patients with cirrhosis

Adverse effects of Afentanil and Nalbuphine in cirrhotic patients undergoing painless gastroscopy: a prospective, double-blind, randomized controlled trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300077062

Enrollment

Unknown

Registered

2023-10-27

Start date

2023-11-01

Completion date

Unknown

Last updated

2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cirrhosis

Interventions

group of Afentanil :Afentanil 5-6ug/kg before the infusion of sedatives.

group of Nalbuphine:Nalbuphine 0.1-0.15mg/kg before the infusion of sedatives.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age 18-80 years, decompensated cirrhosis (Child class B-C), general anesthesia without intubation, BMI 18-28 kg/m2.

Exclusion criteria

Exclusion criteria: Patients with massive hematemesis in the last three days, patients with known general anesthetic allergy before surgery, Mallampatis grade 3-4, renal function grade 2 and above, ASA>III, respiratory tract infection.

Design outcomes

Primary

Measure	Time frame
Intraoperative adverse reactions;Postoperative adverse reaction;	—

Secondary

Measure	Time frame
Changes of hemodynamic ;The amount of sedative;Anesthesia recovery time;Aldrete score;Induction time of anesthesia;	—

Countries

China

Contacts

Public ContactLiuqin Jiang

Shaanxi Nuclear Industry 215 Hospital

jlq215hp@163.com+86 153 3611 6822

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026